AlTi Global Inc. Purchases 2,280 Shares of Johnson & Johnson $JNJ

Key Points

• AlTi Global Inc. increased its stake in Johnson & Johnson by 2.5% during the second quarter, now holding 94,274 shares worth approximately $14.48 million.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, with the ex-dividend date set for November 25th and an annualized yield of 2.7%.
• Recent analyst upgrades have set a consensus target price for Johnson & Johnson at $199.05, reflecting a mix of ratings from "Strong Buy" to "Hold."

AlTi Global Inc. raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 94,274 shares of the company's stock after purchasing an additional 2,280 shares during the period. AlTi Global Inc.'s holdings in Johnson & Johnson were worth $14,477,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in JNJ. GFG Capital LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the first quarter worth $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $190.38 on Friday. The stock has a market cap of $458.69 billion, a P/E ratio of 18.38, a P/E/G ratio of 2.26 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.76. The company has a fifty day moving average price of $182.26 and a two-hundred day moving average price of $166.13. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 50.19%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on JNJ. Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a "market perform" rating in a research report on Monday, October 6th. JPMorgan Chase & Co. increased their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Citigroup increased their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a "buy" rating in a report on Wednesday, October 15th. Finally, Daiwa Capital Markets upgraded shares of Johnson & Johnson from a "neutral" rating to an "outperform" rating and set a $203.00 target price for the company in a report on Monday, October 20th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $199.05.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.